使用选择性雌激素受体调节剂（SERM）预防乳腺癌。
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
作者信息
Powles Trevor J
机构信息
Parkside Oncology Centre, Parkside, Wimbledon, London SW19 5NB, UK.
出版信息
Breast Cancer Res. 2006;8(5):111. doi: 10.1186/bcr1601.
Abstract
Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44-72% and osteoporotic fractures risk by 30-50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene.
摘要
超过25000名女性参与的安慰剂对照试验表明，他莫昔芬可将乳腺癌风险降低约40%，将骨质疏松性骨折风险降低约32%。同样，近18000名女性参与的安慰剂对照试验表明，雷洛昔芬可将乳腺癌风险降低44%-72%，将骨质疏松性骨折风险降低30%-50%。他莫昔芬与雷洛昔芬的直接对比显示，二者在降低乳腺癌和骨质疏松性骨折风险方面效果相似，但雷洛昔芬的毒性更小。
相似文献
1
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).使用选择性雌激素受体调节剂（SERM）预防乳腺癌。
Breast Cancer Res. 2006;8(5):111. doi: 10.1186/bcr1601.
2
Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.在乳腺癌风险增加的绝经后女性中，选择性雌激素受体调节剂治疗的风险、益处及对生活质量的影响。
Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af.
3
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.STAR试验：雷洛昔芬作为绝经后女性降低乳腺癌风险药物的证据。
J Natl Compr Canc Netw. 2007 Sep;5(8):719-24.
4
Prevention of hormone-related cancers: breast cancer.激素相关癌症的预防：乳腺癌
J Clin Oncol. 2005 Jan 10;23(2):357-67. doi: 10.1200/JCO.2005.08.028.
5
Recent results from clinical trials using SERMs to reduce the risk of breast cancer.近期使用选择性雌激素受体调节剂（SERM）降低乳腺癌风险的临床试验结果。
Ann N Y Acad Sci. 2006 Nov;1089:127-42. doi: 10.1196/annals.1386.010.
6
Raloxifene (Evista) for breast cancer prevention in postmenopausal women.雷洛昔芬（易维特）用于绝经后女性预防乳腺癌。
Med Lett Drugs Ther. 2006 May 8;48(1234):37.
7
8
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women].绝经后女性中的选择性雌激素受体调节剂（SERM）
Ned Tijdschr Geneeskd. 1999 Aug 28;143(35):1771-6.
9
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.国家乳腺与肠道外科辅助治疗项目进展：原位导管癌的预防试验及内分泌治疗
Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S.
10
Tamoxifen, raloxifene and the prevention of breast cancer.他莫昔芬、雷洛昔芬与乳腺癌预防
Minerva Endocrinol. 2002 Jun;27(2):127-39.
引用本文的文献
1
Endocrine disrupting chemicals differentially alter intranuclear dynamics and transcriptional activation of estrogen receptor-α.内分泌干扰化学物质差异性地改变雌激素受体-α的核内动力学和转录激活。
iScience. 2021 Oct 7;24(11):103227. doi: 10.1016/j.isci.2021.103227. eCollection 2021 Nov 19.
本文引用的文献
1
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.雷洛昔芬对绝经后妇女心血管事件及乳腺癌的影响。
N Engl J Med. 2006 Jul 13;355(2):125-37. doi: 10.1056/NEJMoa062462.
2
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.他莫昔芬与雷洛昔芬对发生浸润性乳腺癌及其他疾病转归风险的影响：国家外科辅助乳腺和肠道项目（NSABP）他莫昔芬与雷洛昔芬研究（STAR）P-2试验
JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5.
3
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.与易维特相关的持续结果：雷洛昔芬随机试验中绝经后骨质疏松妇女的乳腺癌发病率。
J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61. doi: 10.1093/jnci/djh319.
4
Overview of the main outcomes in breast-cancer prevention trials.乳腺癌预防试验主要结果概述。
Lancet. 2003 Jan 25;361(9354):296-300. doi: 10.1016/S0140-6736(03)12342-2.
5
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.雷洛昔芬治疗绝经后骨质疏松症妇女降低椎体骨折风险：一项3年随机临床试验的结果。雷洛昔芬评估多结局（MORE）研究组。
JAMA. 1999 Aug 18;282(7):637-45. doi: 10.1001/jama.282.7.637.
6
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.雷洛昔芬对绝经后妇女乳腺癌风险的影响：MORE随机试验结果。雷洛昔芬评估的多项结果
JAMA. 1999 Jun 16;281(23):2189-97. doi: 10.1001/jama.281.23.2189.
7
Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.他莫昔芬治疗的乳腺癌患者中的子宫内膜癌：来自国家外科辅助乳腺和肠道项目（NSABP）B-14的研究结果。
J Natl Cancer Inst. 1994 Apr 6;86(7):527-37. doi: 10.1093/jnci/86.7.527.
8
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.为每年接受检查的白人女性预测患乳腺癌的个体概率。
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86. doi: 10.1093/jnci/81.24.1879.
Zotero 插件